Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies.

Related Articles:

• Correction to: Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies. July 2, 2019 Related ArticlesCorrection to: Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019 Jul 01;: Authors: Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, Centonze D, Modugno N Abstract The published version of this article unfortunately contained a mistake in Table 2. CGI-S and CGI-I values has been interchanged.…
• Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. June 22, 2019 Related ArticlesDynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna). 2019 Jun 20;: Authors: Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L Abstract Parkinson's disease (PD) is a very common extrapyramidal movement…
• Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. October 1, 2019 Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clin Neuropharmacol. 2019 Sep/Oct;42(5):172-178 Authors: Bhidayasiri R, Phokaewvarangkul O, Boonpang K, Boonmongkol T, Thongchuem Y, Kantachadvanich N, García Ruiz PJ Abstract OBJECTIVES: A retrospective analysis at 2 specialist centers was undertaken to determine the long-term efficacy of subcutaneous apomorphine infusion (APO), rates and…
• The Patient's Perspective on Shared Decision-Making in Advanced Parkinson's Disease: A Cross-Sectional Survey Study. September 3, 2019 Related ArticlesThe Patient's Perspective on Shared Decision-Making in Advanced Parkinson's Disease: A Cross-Sectional Survey Study. Front Neurol. 2019;10:896 Authors: Nijhuis FAP, van den Heuvel L, Bloem BR, Post B, Meinders MJ Abstract Background: Choosing between deep brain stimulation (DBS), Levodopa-Carbidopa intestinal gel (LCIG), or continuous subcutaneous Apomorphine infusion (CSAI) in advanced Parkinson's disease is a complex decision. It is paramount…
• Continuous subcutaneous apomorphine monotherapy in Parkinson's disease. March 30, 2019 Related ArticlesContinuous subcutaneous apomorphine monotherapy in Parkinson's disease. Ann Agric Environ Med. 2019 Mar 22;26(1):133-137 Authors: Papuć E, Trzciniecka O, Rejdak K Abstract INTRODUCTION AND OBJECTIVE: Continuous subcutaneous apomorphine (APO) treatment is one of the 3 therapeutic options for advanced Parkinson's disease (PD), in addition to deep brain stimulation (DBS) and intrajejunal levodopa. Data from previously performed studies show that…
• Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. September 2, 2019 Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019 Aug 31;: Authors: Carbone F, Djamshidian A, Seppi K, Poewe W Abstract Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine,…
• Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study. November 1, 2019 Related ArticlesSafety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study. Rev Neurol (Paris). 2019 Oct 23;: Authors: Blaise AS, Baille G, Carrière N, Devos D, Dujardin K, Grolez G, Kreisler A, Kyheng M, Moreau C, Mutez E, Seguy D, Defebvre L Abstract BACKGROUND: Treatment with levodopa-carbidopa intestinal gel (LCIG) can effectively relieve motor and…
• Old Drugs, New Delivery Systems in Parkinson's Disease. June 5, 2019 Related ArticlesOld Drugs, New Delivery Systems in Parkinson's Disease. Drugs Aging. 2019 Jun 03;: Authors: Gupta HV, Lyons KE, Pahwa R Abstract Levodopa is the mainstay of treatment in Parkinson's disease (PD). As the disease progresses, variations in plasma levodopa levels lead to motor fluctuations. The common reasons behind variations in the plasma levels include delayed gastric emptying, small intestinal…
• Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction. May 17, 2019 Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction. Urol Int. 2019 May 16;:1-7 Authors: Soebadi MA, Hakim L, Van der Aa F, De Ridder D Abstract AIMS: To determine factors for treatment persistence in a real-life cohort of adult neurogenic lower urinary tract dysfunction. METHODS: We reviewed records of patients with neurogenic lower urinary tract dysfunction and mirabegron prescriptions. Exclusion…
• Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation. September 14, 2019 Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation. Ann Clin Transl Neurol. 2019 Sep 13;: Authors: Elkouzi A, Ramirez-Zamora A, Zeilman P, Barabas M, Eisinger RS, Malaty IA, Okun MS, Almeida L Abstract OBJECTIVE: To evaluate the effectiveness of levodopa-carbidopa intestinal gel (LCIG) as an add-on rescue therapy following deep brain…
• Study proves the effectiveness of Parkinson’s drug apomorphine May 11, 2017 Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo. The reduction in ‘off’ time was achieved without an increase in dyskinesias and…
• CVT-301 for the treatment of Parkinson's disease. May 21, 2019 Related ArticlesCVT-301 for the treatment of Parkinson's disease. Expert Rev Neurother. 2019 May 19;: Authors: Shpiner DS, Bette S, Di Luca DG, Margolesky J Abstract INTRODUCTION: For patients with Parkinson's disease (PD), the treatment of motor and nonmotor fluctuations is tantamount to maintaining quality of life. Subcutaneous apomorphine has been the only commercially available rescue therapy for the treatment of…
• What's Hot in PD?: Subcutaneous Apomorphine Infusions May 3, 2017 Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited…
• What's Hot in PD?: Subcutaneous Apomorphine Infusions May 3, 2017 Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited…
• What's Hot in PD?: Subcutaneous Apomorphine Infusions May 3, 2017 Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited…
• Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. September 12, 2019 Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol. 2019;10:934 Authors: Liu XD, Bao Y, Liu GJ Abstract Background: Currently, some advanced treatments such as Levodopa-Carbidopa intestinal gel infusion (LCIG), deep-brain stimulation (DBS), and subcutaneous apomorphine infusion have become alternative strategies for advanced Parkinson's disease (PD). However,…
• TOLEDO: Apomorphine Reduces Parkinson's 'Off' Time April 20, 2017 Phase 3 TOLEDO trial results show that patients with PD given subcutaneous apomorphine infusion had significantly greater reductions in treatment 'off' time than did those receiving placebo infusions. Medscape Medical News
• What’s Hot in PD? Choosing Between Subcutaneous Apomorphine Infusions, Intestinal Pumps (Duopa) and Deep Brain Stimulation: Implications of the TOLEDO Trial August 7, 2018 Over time, surgical therapies have improved treatment options for a generation of people with Parkinson’s disease (PD) who experience worsening motor fluctuations and dyskinesia. Lesion therapies, such as deep brain stimulation (DBS), are powerful options for people with these troublesome symptoms. Levodopa/carbidopa intestinal pump therapy (Duopa) provide an option for symptom relief without brain surgery. In this month’s edition of…
• Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. March 25, 2019 Related ArticlesContemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs. 2019 Mar 23;: Authors: Cabreira V, Soares-da-Silva P, Massano J Abstract Parkinson's disease (PD) is a chronic, progressive condition affecting around 1% of the population older than 60 years. Upon long-term treatment with levodopa, the mainstay of treatment in PD, most patients, especially younger ones…
• Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine - GlobeNewswire August 5, 2019 Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine  GlobeNewswireParkinson's Disease Therapeutic Apomorphine Delivery via the h-Patch™ Offers Advantages Over Subcutaneous Injections and Bulky Belt-worn Pump Devices ...